Research Article
Construction of a Prognostic Immune-Related LncRNA Risk Model for Gastric Cancer
Figure 7
The verification of clinical role of RP11-617F23.1 in gastric cancer. (a) RP11-617F23.1 was significantly upregulated in human GC tissues (n = 64) compared with their corresponding adjacent tissues (n = 64). (b) RP11-617F23.1 was upregulated in gastric cancer cell lines compared with gastric epithelial cell. (c, d) Patients with high RP11-617F23.1 expression in tumor tissues had poorer overall survival (OS) and disease‐free survival (DFS) than patients with low RP11-617F23.1 expression (, ).
(a) |
(b) |
(c) |
(d) |